Abstract
The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves a rtificial hydrophobiz ation of peptides and proteins that facilitates the delivery of the se pe ptides a nd pr oteins ac r oss BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
Keywords: blood-brain barrier, drug efflux, drug delivery, fatty acylation, nanoge, nanoparticles, pluronic block copolymers, poloxamer.
Current Pharmaceutical Design
Title: New Technologies for Drug Delivery Across the Blood Brain Barrier
Volume: 10 Issue: 12
Author(s): A. V. Kabanov and E. V. Batrakova
Affiliation:
Keywords: blood-brain barrier, drug efflux, drug delivery, fatty acylation, nanoge, nanoparticles, pluronic block copolymers, poloxamer.
Abstract: The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves a rtificial hydrophobiz ation of peptides and proteins that facilitates the delivery of the se pe ptides a nd pr oteins ac r oss BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
Export Options
About this article
Cite this article as:
Kabanov V. A. and Batrakova V. E., New Technologies for Drug Delivery Across the Blood Brain Barrier, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384826
DOI https://dx.doi.org/10.2174/1381612043384826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Curcumin as an Adjuvant to Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies
Current Molecular Medicine Effect of Resveratrol and Tiron on the Inactivation of Glyceraldehyde-3- phosphate Dehydrogenase Induced by Superoxide Anion Radical
Current Medicinal Chemistry Ketamine: New Indications for an Old Drug
Current Drug Targets Analysis of Univariate and Multivariate Filters Towards the Early Detection of Dementia
Recent Advances in Computer Science and Communications Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Current Neuropharmacology Acute Effects of Neutrophil-Derived Oxidative Stress on Pulmonary Microvasculature
Current Respiratory Medicine Reviews Lentiviral Transgenesis - A Versatile Tool for Basic Research and Gene Therapy
Current Gene Therapy Soothing the Inflamed Brain: Effect of Non-Steroidal Anti-Inflammatory Drugs on Alzheimers Disease Pathology
CNS & Neurological Disorders - Drug Targets Neurodegeneration with Dementia: From Fundamentals of Pathology to Clinical Imaging by MRI and SPECT.
Current Medical Imaging Alkylglycerol Lipid Precursors: A Review of Therapeutic Strategies for Plasmalogen Replacement
Current Organic Chemistry Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry Melatonin and Its Therapeutic Potential in Neuroprotection
Central Nervous System Agents in Medicinal Chemistry Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Differences Between Parkinson’s and Huntington’s Diseases and Their Role for Prioritization of Stem Cell-Based Treatments
Current Molecular Medicine Nano Phytomedicine Based Delivery System for CNS Disease
Current Drug Metabolism Editorial (Hot Topic: Monoamine Oxidase as a Target in Medicinal Chemistry and Drug Discovery)
Current Topics in Medicinal Chemistry Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research